Narcolepsy is characterized by excessive daytime sleepiness (EDS), cataplexy, direct onsets of rapid eye movement (REM) sleep from wakefulness (DREMs) and deficiency of orexins, neuropeptides that promote wakefulness largely via activation of histamine (HA) pathways. The hypothesis that the orexin defect can be circumvented by enhancing HA release was explored in narcoleptic mice and patients using tiprolisant, an inverse H 3 -receptor agonist. In narcoleptic orexin −/− mice, tiprolisant enhanced HA and noradrenaline neuronal activity, promoted wakefulness and decreased abnormal DREMs, all effects being amplified by co-administration of modafinil, a currentlyprescribed wake-promoting drug. In a pilot single-blind trial on 22 patients receiving a placebo followed by tiprolisant, both for 1 week, the Epworth Sleepiness Scale (ESS) score was reduced from a baseline value of 17.6 by 1.0 with the placebo ( p > 0.05) and 5.9 with tiprolisant ( p < 0.001). Excessive daytime sleep, unaffected under placebo, was nearly suppressed on the last days of tiprolisant dosing. H 3 -receptor inverse agonists could constitute a novel effective treatment of EDS, particularly when associated with modafinil.
Introduction
Narcolepsy is a rare disabling sleep disorder with a prevalence of 0.02-0.05%; it is characterized by excessive daytime sleepiness (EDS) and abnormal rapid eye movement (REM or paradoxical) sleep manifestations, including cataplexy (sudden loss of muscle tone triggered by strong emotions), direct transitions from wakefulness to REM sleep (DREMs), sleep paralysis and hypnagogic hallucinations (Baumann and Bassetti, 2005; Mignot, 2005; Mignot and Nishino, 2005; Dauvilliers et al., 2007) .
Recent data in animal models revealed that deficient orexin (also known as hypocretin) transmission causes narcolepsy (Lin et al., 1999; Chemelli et al., 1999) . A marked decrease in orexin-A levels in the cerebrospinal fluid and in the number of orexin neurons in post-mortem brain tissues was also reported in patients with narcolepsy with cataplexy (Nishino et al., 2000) . 
